Targeting ORMDL2 in glioblastoma through integrated landscape of high-throughput sequencing and pharmacogenomic analysis
International Journal of Medical Sciences · 2025
DOI: 10.7150/ijms.116954 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Medical Sciences, 2025. Verfasst von Fitria Sari Wulandari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Membrane Proteins. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is characterized by rapid progression, therapeutic resistance, and a profoundly immunosuppressive tumor microenvironment. Emerging evidence suggests that endoplasmic reticulum (ER)-associated macromolecules play critical roles in tumor adaptation. In this study, we performed a multi-omics investigation of orosomucoid-like protein 2 (ORMDL2), a conserved ER membrane protein involved in sphingolipid biosynthesis and ER stress regulation, and uncovered its regulatory functions in GBM progression. Transcriptomic analyses across The Cancer Genome Atlas (TCGA), and Chinese Glioma Genome Atlas (CGGA) revealed elevated ORMDL2 expression in GBM tissues which causes poor prognosis. The MetaCore pathway and Gene Set Enrichment Analysis (GSEA) identified ORMDL2's involvement in antigen presentation via a major histocompatibility complex I (MHC class I), unfolded protein response (UPR), and mitochondrial apoptotic signaling. Single-cell RNA-sequencing data and the Human Protein Atlas showed ORMDL2 enrichment in tumor stromal cells. Pharmacogenomic correlation via the Genomics in Drug Sensitivity in Cancer (GDSC) and Cancer Therapeutics Response Portal (CTRP) database suggested that ORMDL2 expression was associated with resistance to DNA damage response inhibitors such as etoposide, doxorubicin, talazoparib, and might interact with sphingolipid-targeting compounds. Collectively, our findings establish ORMDL2 as a multi-functional macromolecular regulator of immune suppression and therapeutic resistance in GBM, providing new mechanistic insights and potential targets for translational medicines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
- Department of Surgery, Division of Neurosurgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
- TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan.
- Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Himachal Pradesh, 173229, India.
- Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life Sciences, Jl. Pulomas Barat Kav 88, Jakarta Timur, 13210, Indonesia.
Zitieren
APA
Wulandari, F. S., Wang, C. Y., Kumar, S., Ly, N. P., Ngadio, J. L., Solomon, D. D., Xuan, D. T. M., Sutandi, G. N., Lin, H. Y., Lin, H. R., Lee, Y. K., Yang, H. C., Tsai, M. C., & Ko, C. C. (2025). Targeting ORMDL2 in glioblastoma through integrated landscape of high-throughput sequencing and pharmacogenomic analysis. International Journal of Medical Sciences. https://doi.org/10.7150/ijms.116954
Vancouver
Wulandari FS, Wang CY, Kumar S, Ly NP, Ngadio JL, Solomon DD, et al. Targeting ORMDL2 in glioblastoma through integrated landscape of high-throughput sequencing and pharmacogenomic analysis. International Journal of Medical Sciences. 2025. doi:10.7150/ijms.116954
BibTeX
@article{Wulandari2025,
author = {Wulandari, Fitria Sari and Wang, Chih-Yang and Kumar, Sachin and Ly, Ngoc Phung and Ngadio, Juan Lorell and Solomon, Dahlak Daniel and Xuan, Do Thi Minh and Sutandi, Gabriela Natasha and Lin, Hung-Yun and Lin, Hui-Ru and Lee, Yung-Kuo and Yang, Hao-Chien and Tsai, Ming-Cheng and Ko, Ching-Chung},
title = {Targeting ORMDL2 in glioblastoma through integrated landscape of high-throughput sequencing and pharmacogenomic analysis},
journal = {International Journal of Medical Sciences},
year = {2025},
doi = {10.7150/ijms.116954}
}
EUVIMED